Today: 27 June 2026
Circle Stock Gives Back Its Earnings Pop as Arc Ambition Meets Rate Reality
12 May 2026
3 mins read

Circle Stock Gives Back Its Earnings Pop as Arc Ambition Meets Rate Reality

New York, May 12, 2026, 12:05 EDT

  • Circle shares jolted after Q1 numbers—robust USDC flow and the Arc token presale drew in buyers. Still, the advance stalled, with revenue, rates, and valuation setting the upper limit.
  • CRCL’s price action signals more than just an earnings move. The stock hit nearly $140 at its session peak, then slid down to about $125 before noon.
  • Bulls talk up Circle as a future digital-dollar infrastructure play. Bears, though, point to a reserve-income business still tied closely to rates—and costs climbing.

Circle Internet Group shares slid by late morning Tuesday, erasing an earlier pop after earnings. CRCL was changing hands at $125.05 as of 11:49 a.m. EDT, off roughly 5.1% from where it ended Monday. The stock had climbed to $139.63 before dropping to $122.20. In short: a quick rally gave way as traders reassessed the revenue and interest rate numbers.

Circle isn’t getting the typical payments-company valuation yet. Its main product, USDC, is a stablecoin pegged to $1, with revenue coming largely from interest earned on the reserves—cash, bank deposits, and short-term Treasuries—behind those tokens. As a result, the stock moves not just with trends in crypto adoption, but also on the Fed’s rate outlook, returns on its reserves, and how much it splits with distribution partners.

The quarter gave both sides ammo. Circle reported USDC in circulation up 28% year-over-year, hitting $77.0 billion. On-chain transaction volume soared 263% to $21.5 trillion. Total revenue and reserve income climbed 20% to $694 million. Adjusted EBITDA came in at $151 million, up 24%. Net income, however, slipped 15% to $55 million.

That’s the reason shares couldn’t hang onto those early gains. Revenue came in at $694 million—shy of a published estimate for $714.88 million—though EPS of $0.21 edged past the same forecast. When a stock’s already priced for growth, a “mixed” quarter like this can trigger a sharp intraday pullback, particularly with the broader market under pressure after a hotter inflation report. Investing.com

On the call, management steered the narrative well past reserve income. CEO Jeremy Allaire branded it the “largest platform shift in the history of the Internet,” drawing a line from Circle’s stablecoin infrastructure to AI agents, programmable payments, and fresh blockchain plumbing. Ambition ran high, but the pitch wasn’t pure hype—Circle is making the case that it can generate fee revenue without being chained to Treasury yields. The Motley Fool

Arc stands out. Circle pulled in $222 million through a presale for the ARC token, assigning the network a $3 billion fully diluted valuation. The investor lineup, according to the company, features a16z crypto, BlackRock, ARK Invest, Apollo Funds, and Standard Chartered Ventures. Mizuho bumped its price target up to $135 from $120 while holding to its Neutral call, noting that Arc might drive fresh revenue via transaction fees and staking rewards. Circle

The bull thesis? Circle is pushing USDC beyond just a balance-sheet asset, aiming to make it the backbone of financial operations. “It’s tough to be bearish” on Circle’s long-term outlook, Zacks stock strategist Andrew Rocco said in comments to Reuters. And the company’s own data underlines that optimism: higher platform volume, more USDC flowing through the system, and a growing list of enterprise applications—think treasury, settlement, even prediction-market collateral. Reuters Circle

The bear case hasn’t gone away. Reserve return rate slipped to 3.5%, a 0.66 percentage point drop from last year. At the same time, distribution, transaction and other costs reached $407 million, and adjusted operating expenses jumped 32%. Circle’s business is expanding, but that growth isn’t coming cheap—it’s costing more to get USDC out there and to fund the company’s product expansion plans meant to broaden the business.

Rates are a double-edged sword right now. On Polymarket, traders have put just 62% odds on the Fed making zero rate cuts in 2026, and for June, that same market’s pricing in a 98% likelihood the Fed stays put. A DeFi Rate aggregate, pulling in numbers from Kalshi, Polymarket, and Gemini, pegged June’s hold at 97.5%. Circle, for one, benefits from the income boost that higher-for-longer brings to its reserves. But on the flipside, that same environment is still weighing on growth stocks trading at high multiples—investors are staying picky. Polymarket Polymarket

The divide in reactions comes down to peer context. Tether still holds the crown as the top stablecoin by market cap. Meanwhile, Coinbase stands out as both a crypto bellwether and key Circle ally. Reuters pointed out that Coinbase’s latest numbers showed a drop in trading activity. That’s part of why Circle’s USDC performance caught attention—investors are gravitating toward crypto infrastructure that’s reliable even when the frenzy fades.

Regulation remains front and center. The Senate Banking Committee plans to take up the Clarity Act on May 14, targeting the rules for token classification and the terms for crypto firms working with banks. As for Circle, the stakes are concrete: clearer laws might boost stablecoin uptake, but tighter limits on rewards and banking-style features could reshape both USDC’s distribution and revenue streams.

This drop isn’t about faith in Circle’s business model—it’s the timeline that’s getting re-evaluated. Investors were initially on board with Circle’s pitch to evolve into a bigger internet-finance player, but as the numbers came in, the stock took a hit. For now, Circle’s value still swings with reserve yields, expenses, oversight, and a punchy price tag. What matters next is less about a single EPS print and more about whether USDC use, Arc’s revenue engine, and CPN payments volume can actually deliver on the promise beyond reserves.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • ImmunityBio surges 11.8% on heavy volume ahead of Russell 1000 reconstitution
    June 27, 2026, 10:50 AM EDT. ImmunityBio (NASDAQ:IBRX) shares rose 11.8% to $8.71 on Friday, with trading volume hitting 41.2 million, nearly triple its average daily volume. The spike accounted for 46% of the stock's last five-day volume as investors react to the upcoming FTSE Russell June 2026 index reconstitution, effective Monday. The company's market cap approaches $9.1 billion, exceeding the Russell 1000 inclusion threshold of $5.7 billion. A director's insider sale of 25,000 shares was minimal relative to volume and unlikely to impact price. Investors will watch Monday's opening for sustained demand indicating broader support beyond index-related trading. ImmunityBio reported robust product revenue growth of 168% year-over-year, driven by its Anktiva product, and holds strong cash reserves of $381 million, underscoring focus on U.S. scaling and global expansion.

Latest articles

GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

27 June 2026
GameStop surged 3.57% to $21.76 and jumped after hours as it forecast FY2026 adjusted EBITDA above $600 million, nearly doubling from 2025; with a $9.76 billion market cap now close to its $9.7 billion in cash, securities, digital assets, and collateral, investors are weighing whether GameStop’s cash-rich balance sheet can support equity while Ryan Cohen pursues an eBay bid.
ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

27 June 2026
ImmunityBio surged 11.8% to $8.71 on Friday with volume tripling its average, as Russell index reconstitution took effect; Monday’s trading will reveal if demand persists or if the spike was driven by index flows, with no imminent company events and recent insider selling accounting for just 0.06% of Friday’s volume.
Lucid (NASDAQ:LCID) jumps, adding about $312 million after $158 million cost plan

Lucid (NASDAQ:LCID) jumps, adding about $312 million after $158 million cost plan

27 June 2026
Lucid surged 15.6% Friday, adding $312 million in equity value—almost double the $158 million in annualized savings from this week’s restructuring plan that cut 18% of its U.S. workforce. Friday’s volume equaled 54% of reported short interest, but the rally outpaced cost-cutting fundamentals, leaving less room for further gains based solely on headcount cuts.
Court ruling on student loans hits private lenders’ health grad loan push

Court ruling on student loans hits private lenders’ health grad loan push

27 June 2026
Judge blocks narrow “professional degree” rule, letting more health-care grad students keep higher federal loan caps; $7.87B in 2023-24 borrowing above new limits remains in federal market, trimming but not eliminating the $4.5B-$5B annual private loan growth Sallie Mae projected from Grad PLUS loan cuts.
SMH vs SOXX vs SOXL: AI Chip ETF Rally Hits Its Hardest Test Yet
Previous Story

SMH vs SOXX vs SOXL: AI Chip ETF Rally Hits Its Hardest Test Yet

Under Armour’s Selloff Shows Investors Still Don’t Trust the Turnaround Math
Next Story

Under Armour’s Selloff Shows Investors Still Don’t Trust the Turnaround Math

Go toTop